Free Trial
ETR:MOR

MorphoSys (MOR) Stock Price, News & Analysis

MorphoSys logo
€67.25
0.00 (0.00%)
(As of 08/20/2024)

About MorphoSys Stock (ETR:MOR)

Key Stats

Today's Range
€66.70
€67.30
50-Day Range
€67.00
€67.25
52-Week Range
€14.52
€69.75
Volume
5,144 shs
Average Volume
153,687 shs
Market Capitalization
$2.53 billion
P/E Ratio
N/A
Dividend Yield
1.26%
Price Target
N/A
Consensus Rating
N/A

Company Overview

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Stock News Headlines

[Just Released] Jovine's Emergency Briefing inside
People didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some readers walked away with gains as high as 459%, 646% even 700% - while the stock market got cut in half. You don't want to ignore his latest warning.
ERAS Sep 2024 2.500 put (ERAS240920P00002500)
MORF Sep 2024 40.000 put (MORF240920P00040000)
See More Headlines

MOR Stock Analysis - Frequently Asked Questions

MorphoSys' stock was trading at €34.00 at the beginning of the year. Since then, MOR stock has increased by 97.8% and is now trading at €67.25.
View the best growth stocks for 2024 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), SolarEdge Technologies (SEDG), Gilead Sciences (GILD), AbbVie (ABBV) and Abbott Laboratories (ABT).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
730
Year Founded
N/A

Profitability

Net Income
$-468,570,000.00
Net Margins
-190.61%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$241.47 million
Cash Flow
€129.73 per share
Book Value
(€6.96) per share

Miscellaneous

Free Float
N/A
Market Cap
$2.53 billion
Optionable
Not Optionable
Beta
0.66
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (ETR:MOR) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners